SL-28 for Advanced Solid Tumours
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Second Life Therapeutics is developing SL-28, an allogeneic, non-genetically modified cell-based therapy for the treatment of advanced solid tumours. The company has recently demonstrated a novel, non-genetic approach to modulate immune cell activity through targeted manipulation of the Universal Receptive System. The purpose of this open label, multi-center clinical trial is to evaluate the anti-tumor activity, safety, and pharmacokinetics, single-agent SL-28 in patients with a diverse array of solid tumors. The study includes an initial Phase 1 dose escalation to determine recommended dose(s) for expansion of SL-28 as a monotherapy and Phase 2 expansion cohorts. The study will enroll patients with advanced solid tumours, including those who failed previous lines of chemo- and immunotherapies.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Oczekiwana długość życia co najmniej 3 miesiące
- •Potwierdzony zaawansowany rak (nieoperacyjny, przerzutowy lub rozprzestrzeniający się)
- •Rak, który nie odpowiedział na standardowe leczenie, immunoterapię lub leczenie ukierunkowane
- •Bądź w dobrym ogólnym stanie zdrowia (ECOG 0-1)
- •Prawidłowe funkcjonowanie wątroby, nerek i tworzącej się krwi
- •Dla kobiet: nie być w ciąży i używać antykoncepcji przez 90 dni po leczeniu
- •Dla mężczyzn: nie oddawać nasienia przez 90 dni po leczeniu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 10, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
The Southern Oncology Clinical Research Unit (SOCRU)
Adelaide, Australia
Trial contact
George Tetz, MD, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/10/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.